

Client Update

BioReference® | GenPath®

August 2023

Page 1 of 8

Test Name	Test Code	Effective Date
Anti-Thyroglobulin Ab. (ATG)	0041-4	August 29, 2023

Due to an update in testing platform, the specimen stability, methodology and reference range for **Anti-Thyroglobulin Ab. (ATG)** have been updated. Please refer to the table below for details.

Previous Test Information		New Test Information
Stability	Stability: 7 days / Frozen stability: 14 days	Stability: 4 days / Frozen stability: 2 months
Methodology	Chemiluminescence	Electrochemiluminescence
Reference Range	<40 IU/mL (Gender: both)	<116 IU/mL

Test Name	Test Code	Effective Date
Beta-2 Microglobulin Serum	0262-6	August 29, 2023

Due to an update in testing platform, the specimen stability, methodology and reference range for **Beta-2 Microglobulin Serum** have been updated. Please refer to the table below for details.

Previous Test Information		New Test Information
Stability	7 days, frozen 14 days	3 days, frozen 6 months
Methodology	Chemiluminescent	Immunoturbidimetric
Reference Range	<2.16 mg/L	<60 years 0.8-2.4mg/L >60 years <=3.0mg/L

Test Name	Test Code	Effective Date
Conventional Pap Slides	1100-7 and 1960-4	October 1, 2023

Cervical cytology for uterine cervical cancer screening has transitioned from conventional smears to liquid based cytology. Advantages of this include significantly lower rates of unsatisfactory pap smear results, HPV testing from the same specimen and the ability to utilize digital imaging platforms. Due to this, BioReference will no longer be offering the conventional pap smear as part of our test menu.

Effective October 1, **Conventional Pap Slide(s) (test code 1100-7)** and **Pap Smear Manual Screen (test code 1960-4)** will be retired. A liquid based Pap using ThinPrep or SurePath can be ordered in place of a conventional Pap with test code 1962-0

	Previous Test Information	Previous Test Information	Alternate Test Information
Test Name	Conventional Pap Slides	Pap Smear Manual Screen	Liquid Based Pap
Test Code	1100-7	1960-4	1962-0
Primary Container	Slide GYN	N/A	ThinPrep or SurePath
Turn Around Time*	5 days	5 days	5 days
Transportation Temp	Room Temperature	Room Temperature	Room Temperature
CPT Code(s)**	88148	88164	88175
List Price	\$80.00	\$80.00	\$95.00

Test Name	Test Code	Effective Date
DHEA, Sulfate	0406-9	August 23, 2023

Due to an update in testing platform, the specimen stability, methodology and reference range for **DHEA, Sulfate** have been updated. Please refer to the table and the next page below for details.

Previous Test Information		New Test Information
Stability	Stability: 2 days / Frozen stability: 60 days	Stability: 5 days / Frozen stability: 12 months
Methodology	Chemiluminescence	Electrochemiluminescence

* TAT is based upon receipt of the specimen at the laboratory.

**CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

***Healthcare providers should only order panels if each test in the panel is medically necessary.

Client Update

BioReference® | GenPath®

August 2023

Page 2 of 8

Test Name	Test Code	Effective Date																																																																																																						
Reference Range	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="3">Previous Test Information</th> <th colspan="3">New Test Information</th> </tr> <tr> <th>Age</th> <th>Female (µg/dL)</th> <th>Male (µg/dL)</th> <th>Age</th> <th colspan="2">Children (µg/dL)</th> </tr> </thead> <tbody> <tr> <td>1-5 days</td> <td><200</td> <td><220</td> <td>< 1 week</td> <td colspan="2">108-607</td> </tr> <tr> <td>1 mo-5 yrs</td> <td><60</td> <td><58</td> <td>1-4 weeks</td> <td colspan="2">31.6-431</td> </tr> <tr> <td>6-9 yrs</td> <td><95</td> <td><92</td> <td>1-12 months</td> <td colspan="2">3.4-124</td> </tr> <tr> <td>10-11 yrs</td> <td><260</td> <td><220</td> <td>1-4 years</td> <td colspan="2">0.47-19.4</td> </tr> <tr> <td>12-17 yrs</td> <td>51-455</td> <td>44-531</td> <td>5-9 years</td> <td colspan="2">2.8-85.2</td> </tr> <tr> <th>Age</th> <th>Female (µg/dL)</th> <th>Male (µg/dL)</th> <th>Age</th> <th>Female (µg/dL)</th> <th>Male (µg/dL)</th> </tr> <tr> <td>18-30</td> <td>59-432</td> <td>96-571</td> <td>10-14</td> <td>33.9-280</td> <td>24.4-247</td> </tr> <tr> <td>31-50</td> <td>26-287</td> <td>45-419</td> <td>15-19</td> <td>65.1-368</td> <td>70.2-492</td> </tr> <tr> <td>51-60</td> <td>*</td> <td>22-321</td> <td>20-24</td> <td>148-407</td> <td>211-492</td> </tr> <tr> <td>61-83</td> <td>*</td> <td>15-254</td> <td>25-34</td> <td>98.8-340</td> <td>160-449</td> </tr> <tr> <td colspan="3">* post-menopausal range 15-195 ug/dL</td> <td>35-44*</td> <td>60.9-337</td> <td>88.9-427</td> </tr> <tr> <td></td> <td></td> <td></td> <td>45-54*</td> <td>35.4-256</td> <td>44.3-331</td> </tr> <tr> <td></td> <td></td> <td></td> <td>55-64</td> <td>18.9-205</td> <td>51.7-295</td> </tr> <tr> <td></td> <td></td> <td></td> <td>65-74</td> <td>9.40-246</td> <td>33.6-249</td> </tr> <tr> <td></td> <td></td> <td></td> <td>≥ 75</td> <td>12.0-154</td> <td>16.2-123</td> </tr> </tbody> </table>	Previous Test Information			New Test Information			Age	Female (µg/dL)	Male (µg/dL)	Age	Children (µg/dL)		1-5 days	<200	<220	< 1 week	108-607		1 mo-5 yrs	<60	<58	1-4 weeks	31.6-431		6-9 yrs	<95	<92	1-12 months	3.4-124		10-11 yrs	<260	<220	1-4 years	0.47-19.4		12-17 yrs	51-455	44-531	5-9 years	2.8-85.2		Age	Female (µg/dL)	Male (µg/dL)	Age	Female (µg/dL)	Male (µg/dL)	18-30	59-432	96-571	10-14	33.9-280	24.4-247	31-50	26-287	45-419	15-19	65.1-368	70.2-492	51-60	*	22-321	20-24	148-407	211-492	61-83	*	15-254	25-34	98.8-340	160-449	* post-menopausal range 15-195 ug/dL			35-44*	60.9-337	88.9-427				45-54*	35.4-256	44.3-331				55-64	18.9-205	51.7-295				65-74	9.40-246	33.6-249				≥ 75	12.0-154	16.2-123	August 24, 2023
Previous Test Information			New Test Information																																																																																																					
Age	Female (µg/dL)	Male (µg/dL)	Age	Children (µg/dL)																																																																																																				
1-5 days	<200	<220	< 1 week	108-607																																																																																																				
1 mo-5 yrs	<60	<58	1-4 weeks	31.6-431																																																																																																				
6-9 yrs	<95	<92	1-12 months	3.4-124																																																																																																				
10-11 yrs	<260	<220	1-4 years	0.47-19.4																																																																																																				
12-17 yrs	51-455	44-531	5-9 years	2.8-85.2																																																																																																				
Age	Female (µg/dL)	Male (µg/dL)	Age	Female (µg/dL)	Male (µg/dL)																																																																																																			
18-30	59-432	96-571	10-14	33.9-280	24.4-247																																																																																																			
31-50	26-287	45-419	15-19	65.1-368	70.2-492																																																																																																			
51-60	*	22-321	20-24	148-407	211-492																																																																																																			
61-83	*	15-254	25-34	98.8-340	160-449																																																																																																			
* post-menopausal range 15-195 ug/dL			35-44*	60.9-337	88.9-427																																																																																																			
			45-54*	35.4-256	44.3-331																																																																																																			
			55-64	18.9-205	51.7-295																																																																																																			
			65-74	9.40-246	33.6-249																																																																																																			
			≥ 75	12.0-154	16.2-123																																																																																																			

Insulin, Fasting

1648-5

August 24, 2023

Due to an update in testing platform, the specimen stability, methodology and reference range for **Insulin, Fasting** have been updated. Please refer to the table below for details.

	Previous Test Information	New Test Information
Stability	Stability: 7 days / Frozen stability: 90 days	Stability: 2 days / Frozen stability: 6 months
Methodology	Indirect Fluorescence Assay	Electrochemiluminescence
Reference Range	3.0-25.0 uIU/mL (Gender: Both)	2.6-24.9 uIU/mL

Insulin-Like Growth Factor I

1072-8

September 6, 2023

Due to an update in testing platform, the specimen stability methodology and reference range for **Insulin Like Growth Factor I** have been updated. Please refer to the table below and the following pages for details.

	Previous Test Information			New Test Information		
Stability	Stability: 7 days Frozen stability: 365 days			Stability: 2 days Frozen stability: 28 days		
Methodology	Chemiluminescence			Electrochemiluminescence		
Reference Range	Age	Male (ng/mL)	Female (ng/mL)	Age	Male (ng/mL)	Female (ng/mL)
	0-3	<15-189	<15-272	0.25	12.0-94.1	13.8-86.4
	4-6	47-231	55-248	0.5	11.8-94.6	15.4-92.0
	7-9	55-222	80-233	1	11.8-96.4	18.7-104.0
	10-11	95-315	96-545	2	13.9-104.0	26.1-128.0
	12-13	95-460	147-549	3	18.9-116.0	34.2-155.0
	14-15	211-512	208-444	4	26.8-134.0	43.2-185.0
	16-18	57-426	176-429	5	36.6-156.0	53.0-216.0
				6	47.1-184.0	63.6-250.0
				7	57.5-216.0	75.0-286.0
				8	67.5-254.0	87.3-324.0

- CONTINUED ON NEXT PAGE -

* TAT is based upon receipt of the specimen at the laboratory.

**CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

***Healthcare providers should only order panels if each test in the panel is medically necessary.

GenPath is a division of BioReference | © 2023 BioReference Health, LLC All rights reserved.
481 Edward H. Ross Drive, Elmwood Park, NJ 07407 | tel 800.229.5227 | fax 201.791.1941 | www.bioreference.com

This fax transmission is only intended for current customers of BioReference and its business units and divisions. If you have received this message in error or have other service related questions, please call 1-800-229-5227. If you would like to receive these clinical updates via email rather than fax, please email clientupdate@bioreference.com.

Client Update

BioReference® | GenPath®

August 2023

Page 3 of 8

Test Name	Test Code	Effective Date
	Age (Years) Both (ng/mL)	
	19-21 105-346	9 76.9-296.0 99.9-363.0
	22-24 107-367	10 85.7-343.0 112.0-398.0
	25-29 88-537	11 93.9-392.0 123.0-427.0
	30-34 41-246	12 101.0-434.0 132.0-451.0
	35-39 57-241	13 108.0-467.0 140.0-468.0
	40-44 43-209	14 115.0-489.0 146.0-480.0
	45-49 74-196	15 120.0-501.0 151.0-485.0
	50-54 55-248	16 125.0-503.0 154.0-485.0
	55-59 36-200	17 129.0-495.0 156.0-479.0
	60-64 51-187	18 132.0-476.0 156.0-466.0
	65-69 37-219	19 134.0-450.0 155.0-449.0
	70-79 24-200	20 136.0-421.0 152.0-429.0
	80-90 17-323	21 137.0-394.0 148.0-410.0
		22 137.0-370.0 143.0-392.0
		23 136.0-348.0 138.0-375.0
		24 135.0-328.0 134.0-359.0
		25 132.0-310.0 130.0-343.0
		26 130.0-295.0 126.0-329.0
		27 128.0-282.0 122.0-315.0
		28 125.0-271.0 118.0-303.0
		29 123.0-263.0 115.0-292.0
		30 120.0-257.0 112.0-281.0
		31 118.0-253.0 109.0-271.0
		32 116.0-250.0 107.0-263.0
		33 114.0-247.0 104.0-255.0
		34 111.0-244.0 102.0-248.0
		35 109.0-242.0 100.0-242.0
		36 107.0-239.0 98.3-238.0
		37 105.0-236.0 96.5-234.0
		38 103.0-234.0 94.8-231.0
		39 101.0-231.0 93.1-228.0
		40 98.5-229.0 91.4-227.0
		41 96.4-226.0 89.8-225.0
		42 94.4-223.0 88.1-224.0
		43 92.4-221.0 86.5-222.0
		44 90.5-218.0 84.9-221.0
		45 88.5-216.0 83.3-220.0
		46 86.5-214.0 81.8-219.0
		47 84.6-211.0 80.2-218.0
		48 82.6-209.0 78.7-218.0
		49 80.6-207.0 77.2-217.0
		50 78.7-205.0 75.7-215.0
		51 76.7-203.0 74.3-214.0
		52 74.8-201.0 72.8-212.0
		53 72.8-200.0 71.4-210.0
		54 70.9-198.0 70.0-207.0
		55 68.9-196.0 68.6-204.0
		56 67.0-195.0 67.3-201.0
		57 65.3-194.0 65.9-198.0
		58 63.7-193.0 64.6-194.0

- CONTINUED ON NEXT PAGE -

* TAT is based upon receipt of the specimen at the laboratory.

**CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

***Healthcare providers should only order panels if each test in the panel is medically necessary.

GenPath is a division of BioReference | © 2023 BioReference Health, LLC All rights reserved.
 481 Edward H. Ross Drive, Elmwood Park, NJ 07407 | tel 800.229.5227 | fax 201.791.1941 | www.bioreference.com

This fax transmission is only intended for current customers of BioReference and its business units and divisions. If you have received this message in error or have other service related questions, please call 1-800-229-5227. If you would like to receive these clinical updates via email rather than fax, please email clientupdate@bioreference.com.

Client Update

BioReference® | GenPath®

August 2023

Page 4 of 8

Test Name	Test Code	Effective Date
	59	62.3-192.0 63.3-190.0
	60	61.1-191.0 62.0-186.0
	61	60.0-190.0 60.7-182.0
	62	59.2-189.0 59.5-179.0
	63	58.5-188.0 58.3-176.0
	64	57.9-188.0 57.3-173.0
	65	57.4-187.0 56.3-170.0
	66	56.8-186.0 55.5-168.0
	67	56.3-186.0 54.8-166.0
	68	55.8-185.0 54.2-164.0
	69	55.2-185.0 53.8-163.0
	70	54.7-185.0 53.5-162.0
	71	54.1-184.0 53.3-161.0
	72	53.6-184.0 53.2-160.0
	73	53.0-184.0 53.2-160.0
	74	52.4-184.0 53.3-160.0
	75	51.9-184.0 53.5-160.0
	76	51.3-184.0 53.7-161.0
	77	50.7-184.0 54.0-162.0
	78	50.2-184.0 54.3-163.0
	79	49.6-184.0 54.7-164.0
	80	55.1-166.0

Multiple (See Below)

Multiple (See Below)

August 28, 2023

Due to an update in testing platform, the methodology and reference range for **Multiple ENA Tests** have been updated. Please refer to the table below for details.

Test code	Test name	Previous Reference Range		New Reference Range			Previous Units	New Units
0587	CENP	<20 (Negative)	≥20 (Positive)	<7.0 (Negative)	7.0-10.0 (Equivocal)	>10.0 (Positive)	{CU}	EliA U/mL
0364	DsDNA	<27 (Negative)	27-35 (Inter); >35 (Pos)	<10.0 (Negative)	10.0-15.0 (Equivocal)	>15.0 (Positive)	[IU]/mL	IU/mL
T974	Jo-1	<20 (Negative)	≥20 (Positive)	<7.0 (Negative)	7.0-10.0 (Equivocal)	>10.0 (Positive)	{CU}	EliA U/mL
0868	La	<20 (Negative)	≥20 (Positive)	<7.0 (Negative)	7.0-10.0 (Equivocal)	>10.0 (Positive)	{CU}	EliA U/mL
TA10	Ro52	<20 (Negative)	≥20 (Positive)	<7.0 (Negative)	7.0-10.0 (Equivocal)	>10.0 (Positive)	{CU}	EliA U/mL
TA11	Ro60	<20 (Negative)	≥20 (Positive)	<7.0 (Negative)	7.0-10.0 (Equivocal)	>10.0 (Positive)	{CU}	EliA U/mL
0315	Scl-70	<20 (Negative)	≥20 (Positive)	<7.0 (Negative)	7.0-10.0 (Equivocal)	>10.0 (Positive)	{CU}	EliA U/mL
0851	SmD [^] P-S	<20 (Negative)	≥20 (Positive)	<7.0 (Negative)	7.0-10.0 (Equivocal)	>10.0 (Positive)	{CU}	EliA U/mL
0852	U1RNP	<20 (Negative)	≥20 (Positive)	<5.0 (Negative)	5.0-10.0 (Equivocal)	>10.0 (Positive)	{CU}	EliA U/mL

* TAT is based upon receipt of the specimen at the laboratory.

**CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

***Healthcare providers should only order panels if each test in the panel is medically necessary.

GenPath is a division of BioReference | © 2023 BioReference Health, LLC All rights reserved.
481 Edward H. Ross Drive, Elmwood Park, NJ 07407 | tel 800.229.5227 | fax 201.791.1941 | www.bioreference.com

This fax transmission is only intended for current customers of BioReference and its business units and divisions. If you have received this message in error or have other service related questions, please call 1-800-229-5227. If you would like to receive these clinical updates via email rather than fax, please email clientupdate@bioreference.com.

Client Update

BioReference® | GenPath®

August 2023

Page 5 of 8

Test Name	Test Code	Effective Date
OnkoSight Advanced™ Chronic Lymphoid Neoplasm NGS Panel	TH55-7 (PB/M); TJ93-4 (FFPE)	Immediately
OnkoSight Advanced™ Plasma Cell Myeloma NGS Panel	TL67-3 (PB/BM); TL68-1 (FFPE)	

BioReference® and GenPath® Oncology are pleased to enhance our OnkoSight Advanced NGS panels for Chronic Lymphoid Neoplasms and Multiple Myeloma by incorporating virtual karyotyping into these panels. Copy number alterations (CNAs) are now included in the new section of the OnkoSight Advanced NGS reports for CLL and Multiple Myeloma along with SNVs (single nucleotide variants). This important feature can inform the presence of large-scale, whole chromosome, chromosome arm, large deletion, or large gain in a sample. Traditionally, such analysis has been restricted to fluorescent *in-situ* hybridization (FISH), chromosomal metaphase karyotyping, and microarray.

Adding CNA information alongside SNV analysis enables the detection of chromosomal gains and losses that enhance diagnostic accuracy, prognostic assessments, and therapeutic stratification in CLL and MM cases.

This application may be considered an adjunct or substitute for routine cytogenetic karyotyping, providing the sample tumor burden is >50%. Balanced translocations can be detected by fluorescent *in-situ* hybridization (FISH) and/or by routine karyotyping.

PLEASE NOTE: The Cancer Genomics Laboratory at GenPath will require samples with >50% tumor burden to run the copy number alteration algorithm. Normal findings will not be reported. The Genome-wide Distribution of CNV and SNV section in CLL and Multiple Myeloma reports will appear only when an alteration is detected.

Please reach out to your dedicated Account Executive or call Customer Service if you have any questions about this announcement.

Ribosomal-P	TQ11	August 28, 2023
-------------	------	-----------------

Testing has been validated to be completed in-house at our facility, therefore test information for Ribosomal-P has been updated. Please refer to the table below for details.

	Previous Test Information	New Test Information
Primary Container	SST	SST
Minimum Volume	0.5 mL	40ul per test
Turn Around Time*	5 Days	4 Days
Transportation Temp	Refrigerated	Refrigerated
Stability	7 Days Refrigerated	7 Days Refrigerated
Methodology	Immunoassay	EliA G
Reference Range	<1.0 Neg	<7.0 ELU/mL
Collection Instructions	Fill tube, invert gently 5 times, label with patient name, let stand for minimum of 30 minutes, maximum of 1 hr, spin for 10-15 minutes	Fill tube, invert gently 5 times, label with patient name, let stand for minimum of 30 minutes, maximum of 1 hr, spin for 10-15 minutes
CPT Code(s)**	83516	83516
List Price	\$95.00	\$40

* TAT is based upon receipt of the specimen at the laboratory.

**CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

***Healthcare providers should only order panels if each test in the panel is medically necessary.

Client Update

BioReference® | GenPath®

August 2023

Page 6 of 8

Test Name	Test Code	Effective Date
Sex-Hormone Binding Globulin	0658-5	August 22, 2023

Due to an updated in testing platform, the methodology and reference range for **Sex-Hormone Binding Globulin** have been updated. Please refer to the table below for details.

	Previous Test Information	New Test Information
Methodology	Chemiluminescence	electrochemiluminescence
Reference Range	Male 10-57 nmol/L Female 18-144 nmol/L	Age (yrs) Male (nmol/L) <20 Not Estab. 20-49 16.5-55.9 >or=50 19.3-76.4 Age (yrs) Female (nmol/L) <21 Not Estab. 21-49 24.6-122.0 >or=50 17.3-125.0

REMINDERS

Hepatitis B	Multiple	October 2023
-------------	----------	--------------

Due to state requirements to report pregnancy status for all positive Hepatitis B Virus results, BioReference and GenPath Women's Health will soon require pregnancy status to be indicated upon order entry for the following Hepatitis B test codes:

- 0106-5 Hepatitis B Surface Antigen
- 0197-4 Hepatitis B Panel
- 3389-4 Hepatitis B Virus, DNA, Quantitative, RT-PCR

Order Entry Question	Is the patient pregnant?
Answer Options	Pregnant, Not Pregnant, Not Applicable

Please note that clients with a non-global EMR compendium will need to open a ticket with their EMR vendors to add the additional Ask on Order Entry (AOE) questions manually.

Hep B Surf Ag w/ confirm, Rfx to DNA, Quant, Prenatal	TP85-7	October 2023
---	--------	--------------

We are pleased to share that we will soon be offering **Hepatitis B Surface Antigen (with confirmation), if positive, reflex to DNA, Quant for prenatal patients (Test code: TP85-7)**.

The Centers for Disease Control and Prevention (CDC) recommends that all HBsAg-positive pregnant women should be tested for HBV DNA to guide the use of maternal antiviral therapy during pregnancy for the reduction of HBV transmission to the newborn. Antiviral therapy has been studied as an intervention to reduce perinatal HBV transmission among pregnant women with high HBV DNA levels (e.g., average HBV DNA levels >200,000). Maternal antiviral therapy started at 28–32 weeks' gestation, as an adjunct to HepB vaccine and HBIG administered to the infant shortly after delivery, has been associated with significantly reduced rates of perinatal HBV transmission.

This new test code (TP85) will replace 0106- Hepatitis B Surface Antigen in the standard OB Panels to align with the CDC's recommendations.

	New Test Information
Primary Container	Serum Separator Tube (SST)
Turn Around Time*	1-4 days
Transportation Temp	Refrigerate

* TAT is based upon receipt of the specimen at the laboratory.

**CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

***Healthcare providers should only order panels if each test in the panel is medically necessary.

GenPath is a division of BioReference | © 2023 BioReference Health, LLC All rights reserved.
 481 Edward H. Ross Drive, Elmwood Park, NJ 07407 | tel 800.229.5227 | fax 201.791.1941 | www.bioreference.com

This fax transmission is only intended for current customers of BioReference and its business units and divisions. If you have received this message in error or have other service related questions, please call 1-800-229-5227. If you would like to receive these clinical updates via email rather than fax, please email clientupdate@bioreference.com.

Client Update

BioReference® | GenPath®

August 2023

Page 7 of 8

Test Name	Test Code	Effective Date
Stability	7 days	
Methodology	Electrochemiluminescence Immunoassay	
Reference Range	Non-reactive	
Collection Instructions	Fill tube. Invert 5 times. Label with patient name, must stand for a minimum of 30 minutes, maximum of 1 hour. Spin for 10-15 minutes.	
Profile Components	Hepatitis B Surface Antigen Hepatitis B Virus, DNA, Quantitative, RT-PCR	
CPT Code(s)**	87340 87517 (if reflex is performed)	
List Price	\$52.50 \$350 (if reflex is performed)	
Clinical Utility (If applicable)	Detect acute or chronic hepatitis in pregnant women and ensure proper health department notification of pregnancy and reflexively measure viral load of hepatitis B in pregnancy and determine if antiviral therapy is needed to decrease transmission of Hepatitis B to the fetus when HBsAg is positive.	

Obstetric Panels **Multiple** **October 2023**

BioReference and GenPath strive to ensure that you have the most up to date and guideline driven testing options. Coming in October, we will be making updates to our **Obstetric/Prenatal Panel (Test Code 0008)**, **Obstetric AMA Panel (test code 0010)**, and **Obstetric Panel (Test Code 7307)** to reflect current ACOG and CDC recommendations. Please see the tables on the next page for the anticipated test names changes and test components updates.

	Test Code 0008 - Previous Test Information	Test Code 0008 - New Test Information
Test Name	Obstetric/Prenatal I	Obstetric ACOG Panel w/HIV
Test Components	0039 ANTIBODY SCREEN 0053 CBC WITH DIFF 0142 RPR 0156 ABO/Rh BLOOD TYPE 0973 RUBELLA, IGG	0039 ANTIBODY SCREEN 0053 CBC WITH DIFF 0142 RPR 0156 ABO/Rh BLOOD TYPE 0973 RUBELLA, IGG B688 HIV B125 HEP C ANTIBODY W/RFX RT PCR 0080 URINE CULTURE HEP B SURF AG W/CONF, IF POS, RFX to DNA, TP85 QUANT, PRENATAL

	Test Code 0010 - Previous Test Information	Test Code 0010 - New Test Information
Test Name	Obstetric AMA Panel	Obstetric ACOG Panel w/HIV/CT/GC/Trich
Test Components	0039 ANTIBODY SCREEN 0053 CBC WITH DIFF 0142 RPR 0156 ABO/Rh BLOOD TYPE 0973 RUBELLA, IGG 0106 HEP B SURFACE ANTIGEN	0039 ANTIBODY SCREEN 0053 CBC WITH DIFF 0142 RPR 0156 ABO/Rh BLOOD TYPE 0973 RUBELLA, IGG HEP B SURF AG W/CONF, IF POS, RFX to DNA, TP85 † QUANT, PRENATAL B688 HIV B125 HEP C ANTIBODY W/RFX RT PCR 0080 †† URINE CULTURE A861 †† TRICH (URINE, RNA) 6368 †† CT (URINE, RNA) 6369 †† GC (URINE RNA)

* TAT is based upon receipt of the specimen at the laboratory.

**CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

***Healthcare providers should only order panels if each test in the panel is medically necessary.

Client Update

BioReference® | GenPath®

August 2023

Page 8 of 8

Test Name

Test Code

Effective Date

	Test Code 7307 - Previous Test Information	Test Code 7307- New Test Information
Test Name	Obstetric/Prenatal I	Obstetric ACOG Panel w/out HIV
Test Components	0039 ANTIBODY SCREEN 0053 CBC WITH DIFF 0142 RPR 0156 ABO/Rh BLOOD TYPE 0973 RUBELLA, IGG 0080 URINE CULTURE 0106 HEP B SURFACE ANTIGEN	0039 ANTIBODY SCREEN 0053 CBC WITH DIFF 0142 RPR 0156 ABO/Rh BLOOD TYPE 0973 RUBELLA, IGG 0080 URINE CULTURE HEP B SURF AG W/CONF, IF POS, RFX to DNA, QUANT, PRENATAL TP85 † B125 HEP C ANTIBODY W/RFX RT PCR

†Hepatitis B Surface Antigen (with confirmation), if positive, reflex to DNA, Quant for prenatal patients (Test code: TP85-7) will replace 0106- Hepatitis B Surface Antigen in the standard OB Panels to align with the [Centers for Disease Control and Prevention \(CDC\)](#) recommendation that all HBsAg-positive pregnant women should be tested for HBV DNA to guide the use of maternal antiviral therapy during pregnancy for the reduction of HBV transmission to the newborn.

††When collecting urine culture, please pour off urine into GenProbe Aptima urine tube for CT, GC, Trich

Please refer to the test compendium or online test search for specimen requirements, collection instructions and CPT codes. If you have a favorites or profile currently created within your EMR, test components will need to be updated in September accordingly, in order to *avoid* test not performed (TNP's) due to duplicate orders. If you have any additional questions or need more information, please contact customer service or reach out to your dedicated sales representative.

END

* TAT is based upon receipt of the specimen at the laboratory.

**CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

***Healthcare providers should only order panels if each test in the panel is medically necessary.

GenPath is a division of BioReference | © 2023 BioReference Health, LLC All rights reserved.
 481 Edward H. Ross Drive, Elmwood Park, NJ 07407 | tel 800.229.5227 | fax 201.791.1941 | www.bioreference.com

This fax transmission is only intended for current customers of BioReference and its business units and divisions. If you have received this message in error or have other service related questions, please call 1-800-229-5227. If you would like to receive these clinical updates via email rather than fax, please email clientupdate@bioreference.com.